Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 52Gynecologic 17Other solid neoplasm 4Thoracic 3Genitourinary 3Gastrointestinal 3CNS 3Breast 3Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Mesothelioma, Malignant 2Sarcoma 1Mesothelioma 1Lung Neoplasms 1

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Trabectedin × Thoracic × Clear all
NCT02194231 2020-01-23

ATREUS

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
145 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03496519 2018-10-09

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

University of Colorado, Denver

Phase 1 Withdrawn
SarcomaThoracic

Lung Neoplasms, Sarcoma

NCT00027508 2015-02-24

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

PharmaMar

Phase 2 Terminated
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡